AKINETON Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Akineton, and when can generic versions of Akineton launch?
Akineton is a drug marketed by Abbvie and is included in two NDAs.
The generic ingredient in AKINETON is biperiden hydrochloride. There are five drug master file entries for this compound. Additional details are available on the biperiden hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AKINETON?
- What are the global sales for AKINETON?
- What is Average Wholesale Price for AKINETON?
Summary for AKINETON
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 45 |
| Clinical Trials: | 3 |
| Patent Applications: | 4,109 |
| DailyMed Link: | AKINETON at DailyMed |
Recent Clinical Trials for AKINETON
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| PROADI-SUS | Phase 3 |
| Ministry of Health, Brazil | Phase 3 |
| Hospital Sirio-Libanes | Phase 3 |
US Patents and Regulatory Information for AKINETON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | AKINETON | biperiden lactate | INJECTABLE;INJECTION | 012418-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | AKINETON | biperiden hydrochloride | TABLET;ORAL | 012003-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
